Arianna Morena

Arianna Morena

Auto-generated profile, based on publicly available information

Arianna Morena

Department of Medical Sciences, University of Turin, Turin, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
MGMarco Gatti
Marco Gatti
OFOvidio De Filippo
Ovidio De Filippo
GCGaia Cura Curà
Gaia Cura Curà
VDVeronica Dusi
Veronica Dusi
UVUmberto Di Vita
Umberto Di Vita
Fabrizio D'AscenzoFabrizio D'Ascenzo
Fabrizio D'Ascenzo

26 March 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
VDVeronica Dusi
Veronica Dusi
FAFilippo Angelini
Filippo Angelini
EBEnrico Baldi
Enrico Baldi
ATAntonio Toscano
Antonio Toscano
CGCarol Gravinese
Carol Gravinese
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
Percutaneous stellate ganglion block (PSGB) through single-bolus injection and thoracic epidural anaesthesia (TEA) have been proposed for the acute management of refractory ventricular arrhythmias (VAs). However, data on continuous PSGB (C-PSGB) are scant. The aim of this study is to report our dual-centre experience with C-PSGB and to perform a systematic review on C-PSGB and TEA. Consecutive patients receiving C-PSGB at two centres were enrolled. The systematic literature review follows the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. Our case series (26 patients, 88% male, 60 ± 16 years, all with advanced structural heart disease, left ventricular ejection fraction 23 ± 11%, 32 C-PSGBs performed, with a median duration of 3 days) shows that C-PSGB is feasible and safe and leads to complete VAs suppression in 59% and to overall clinical benefit in 94% of cases. Overall, 61 patients received 68 C-PSGBs and 22 TEA, with complete VA suppression in 63% of C-PSGBs (61% of patients). Most TEA procedures (55%) were performed on intubated patients, as opposed to 28% of C-PSGBs (P = 0.02); 63% of cases were on full anticoagulation at C-PSGB, none at TEA (P < 0.001). Ropivacaine and lidocaine were the most used drugs for C-PSGB, and the available data support a starting dose of 12 and 100 mg/h, respectively. No major complications occurred, yet TEA discontinuation rate due to side effects was higher than C-PSGB (18 vs. 1%, P = 0.01). Continuous PSGB seems feasible, safe, and effective for the acute management of refractory VAs. The antiarrhythmic effect may be accomplished with less concerns for concomitant anticoagulation compared with TEA and with a lower side-effect related discontinuation rate.


26 February 2026 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
FGFederico Giacobbe
Federico Giacobbe
PMPierre Meynet
Pierre Meynet
MBMarco Balducci
Marco Balducci
SCSergio Capoccia
Sergio Capoccia
RCRino Andrea Cimino
Rino Andrea Cimino
GFGaetano Maria De Ferrari
Gaetano Maria De Ferrari
Coronary microvascular dysfunction (CMD) is a key driver of ischemia and prognosis across several non-ischemic cardiomyopathies. This review summarizes the main tools for diagnosing microvascular dysfunction and available evidence on CMD incidence and the prognostic role in patients with cardiomyopathies. In dilated cardiomyopathy, CMD is associated with reduced myocardial blood flow, greater fibrosis, adverse remodeling, and worse outcomes. In hypertrophic cardiomyopathy, CMD is highly prevalent and multifactorial (arteriolar remodeling, reduced capillary density, extravascular compression, diastolic dysfunction, and/or left ventricular (LV) outflow obstruction), correlating with fibrosis, heart failure, and arrhythmias/sudden death. In Takotsubo syndrome, CMD appears acute and reversible, with microvascular spasms as a predominant mechanism and plausible pathophysiologic basis of the event. In arrhythmogenic right ventricular cardiomyopathy, preliminary data show a blunted hyperemic response and autonomic abnormalities that may impair microvascular vasodilation. In infiltrative and storage diseases (amyloidosis and Anderson–Fabry disease), CMD is often early, preceding hypertrophy/fibrosis, and contributes to symptoms, contractile dysfunction, and adverse outcomes; in sarcoidosis, microvascular inflammation reduces coronary flow reserve (CFR) and is associated with events. Targeted therapies remain limited; optimization of risk factors and drugs that modulate endothelial/metabolic function (statins, angiotensin converting enzyme (ACE) inhibitors, vasodilating β-blockers, calcium channel blockers, sodium glucose cotransporter 2 (SGLT2) inhibitors) yielded variable signals; device-based and nonpharmacologic strategies are under investigation. In conclusion, integrating microcirculatory assessment improves risk stratification and may furnish future therapeutic targets across cardiomyopathies.

28 October 2025 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MSMatteo Serenelli
Matteo Serenelli
PCPaolo Cimaglia
Paolo Cimaglia
APAldostefano Porcari
Aldostefano Porcari
ALAndrea Lalario
Andrea Lalario
MMMarco Merlo
Marco Merlo
GSGianfranco Sinagra
Gianfranco Sinagra

19 February 2025 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
FGFederico Giacobbe
Federico Giacobbe
AMArianna Morena
Arianna Morena
FBFrancesco Bruno
Francesco Bruno
MNMarco Nebiolo
Marco Nebiolo
OFOvidio De Filippo
Ovidio De Filippo
FDFabrizio D'AScenzo
Fabrizio D'AScenzo
Introduction: The expanding indications for transcatheter aortic valve implantation (TAVI) to younger, lower-risk patients, entails assessing not only the short-term clinical outcomes but also the long-term considerations for future interventions. The prevalence of coronary artery disease in TAVI patients is relevant, and the optimal timing of percutaneous coronary intervention remains a question. Methods and results: We conducted a systematic literature review and meta-analysis including 20 eligible studies involving 1660 patients who underwent coronary angiography after TAVI. The primary endpoint was the incidence of successful selective coronary re-access. Secondary endpoints included semi-selective and non-selective access rates. The analysis was stratified by balloon-expandable (BEVs) and self-expandable valve (SEVs) types. Successful coronary access after TAVI was feasible in the majority of patients, with a higher success rate observed for the left main (LM) compared to the right coronary artery (RCA). BEVs demonstrated the highest success rates in coronary ostia cannulation, achieving nearly 100% success for both LM and RCA. Among SEVs, the Acurate Neo and Evolut R/PRO showed superior success rates in selective coronary access (68 and 77% for LM; 57 and 72% for RCA, respectively) compared to the CoreValve (46% for LM and 49% for RCA). Notably, the majority of coronary angiograms were performed due to acute coronary syndrome, primarily non-ST-segment elevation myocardial infarction, and unstable angina. Conclusion: Selective coronary engagement after TAVI is generally achievable, with BEVs demonstrating superior success rates compared to SEVs. Among SEVs, the Acurate NEO showed better outcomes than the other types.